WHO ICTRP trial
Islet autoantigen-derived peptides eluted from Human Leucocyte Antigen (HLA)…
ISRCTN20254161 · International Standard Randomised Controlled Trial Number (ISRCTN) · Not Recruiting
Key facts
| Trial ID | ISRCTN20254161 |
|---|---|
| Public title | Islet autoantigen-derived peptides eluted from Human Leucocyte Antigen (HLA) class II molecules as vaccines for the immunotherapy of type 1 diabetes: a safety and proof of concept study in man |
| Primary sponsor | Diabetes Vaccine Development Centre (Australia) |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | United Kingdom |
| Conditions | Type 1 diabetes mellitus Nutritional, Metabolic, Endocrine Diabetes |
| Interventions | A peptide corresponding to amino-acid C19-A3 of proinsulin will be administered in increasing doses, 10, 100 and 1000 micrograms intradermally in the upper arm. Subjects will be divided into three equal groups, one group for each dose of… |
| Registration date | Mar 3, 2006 |
| Target size | 72 |
| Secondary IDs | PI/1-s |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: